目的：探讨自然杀伤细胞（natural killer，NK细胞）腹腔灌注治疗卵巢癌腹腔积液的近期临床效果和安全性。方法： 分析2016年11月至2019年1月在东部战区总医院秦淮医疗区15例接受NK细胞腹腔灌注治疗的卵巢癌腹腔积液患者的临床资 料，采集患者外周血、分离外周血单个核细胞，经培养后收获NK细胞、腹腔内灌注NK细胞悬液（不低于2×109个细胞/次）。检测 治疗前后患者腹腔积液量、血清肿瘤标志物CA-125水平、血清细胞因子IL-2、INF-γ和TNF-α水平，以及外周血淋巴细胞亚群的 变化，观察其临床疗效和不良反应。结果：NK细胞腹腔灌注治疗后，有效率为66.7%，未出现明显的治疗相关不良反应。与治 疗前比较， 治疗 2 周后患者血清肿瘤标志物 CA-125 水平显著下降（P<0.05），IL-15、IFN-γ和TNF-α水平明显升高（P<0.05或 P<0.01），而外周血淋巴细胞亚群无明显变化（均P>0.05）。结论：NK细胞腹腔灌注治疗卵巢癌腹腔积液近期临床效果较好， 不 良反应小，是一种有前景的治疗癌性腹腔积液的方法。

Objective: To investigate the short-term clinical efficacy and safety of intraperitoneal perfusion of natural killer (NK) cells in the treatment of ovarian cancer with ascites. Methods: The clinical data of 15 ovarian cancer patients with ascites effusion, who received NK cell perfusion in the Qinhuai Medical District of the General Hospital of Eastern Theater Command from November 2016 to January 2019, were analyzed. The peripheral blood was collected to isolate the peripheral blood mononuclear cells, and to further obtain the NK cells after culture. NK cell suspension was intraperitoneally perfused into the abdominal cavity (no less than 2×109 cells/ time). The volume of peritoneal effusion, the level of serum tumor marker CA-125, the level of serum cytokines IL-2, INF-γ and TNF-α as well as the changes in peripheral blood lymphocyte subsets were detected before and after the treatment; Moreover, the clinical efficacy and adverse reactions were observed. Results: The effective rate of intraperitoneal perfusion of NK cells was 66.7%, and there were no obvious treatment-related adverse reactions. Compared with before treatment, the serum tumor marker CA-125 level significantly decreased after treatment (P<0.05), and the levels of IL-15, IFN-γ and TNF-α increased significantly (P<0.05 or P<0.01), while there was no significant changes in peripheral blood lymphocyte subsets (all P>0.05). Conclusion: Intraperitoneal infusion of NK cells in the treatment of ovarian cancer associated peritoneal effusion has a good short-term clinical efficacy with little adverse reactions, which is a promising method for the treatment of cancerous peritoneal effusion.

南京军区医学科技创新课题重点项目（No. 15ZD018）